首页 | 本学科首页   官方微博 | 高级检索  
     


The History and Future of Probenecid
Authors:Nathan Robbins  Sheryl E. Koch  Michael Tranter  Jack Rubinstein
Affiliation:(1) Department of Internal Medicine, Division of Cardiovascular Diseases, College of Medicine, University of Cincinnati, 231 Albert Sabin Way ML0542, Cincinnati, OH 45267, USA;(2) Department of Physiology and Cell Biology, University of Cincinnati, Cincinnati, OH, USA;
Abstract:Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.
Keywords:
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号